Important advice for fertile women:
Topamax may cause harm to a baby during pregnancy. If you are a fertile woman, consult your doctor about other possible treatments. Visit your doctor to review your treatment and discuss the risks at least once a year.
Prevention of migraines
Treatment of epilepsy
Risks of topiramate when taken during pregnancy (regardless of the condition for which topiramate is used) are as follows:
There is a risk of harm to the baby during pregnancy if Topamax is used during pregnancy.
Necessity of contraceptive methods for fertile women:
Use of Topamax in girls:
If you are the parent/caregiver of a girl treated with Topamax,you should consult your doctor immediately once your daughter experiences her first menstrual period (menarche). The doctor will inform you about the risks to a baby during pregnancy due to exposure to topiramate during pregnancy, and about the need to use highly effective contraceptive methods.
If you want to become pregnant while taking Topamax:
If you have become pregnant or think you may be pregnant while taking Topamax:
Make sure to read the patient leaflet that you will receive from your doctor. The patient leaflet is also available by scanning a QR code; see section6 “Other sources of information”. A patient leaflet is provided with the Topamax packaging to remind you of the risks of topiramate during pregnancy.
Breastfeeding
The active ingredient in Topamax (topiramate) passes into breast milk. There have been reports of effects in breastfed babies of mothers treated with Topamax, including diarrhea, feeling sleepy, feeling irritable, and low weight gain. Therefore, your doctor will discuss with you whether to stop breastfeeding or whether to stop taking Topamax. Your doctor will take into account the importance of the benefits for the mother and the risk to the baby.
Mothers who are breastfeeding and taking Topamax should inform their doctor as soon as possible if the baby experiences anything unusual.
Driving and operating machinery
You may experience dizziness, fatigue, and visual disturbances during treatment withTopamax. Do not drive or operate tools or machinerywithout talking to your doctor first.
Topamax contains lactose
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medicine.
Other excipients
This medicine contains less than 1mmol of sodium (23mg) per tablet; this is essentially “sodium-free”.
Follow exactly the administration instructions for this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Girls and fertile women:
Topamax treatment should begin and continue under the supervision of a doctor experienced in treating epilepsy or migraine. Visit your doctor to review your treatment at least once a year.
If you take more Topamax than you should:
You may experience an overdose if you are taking another medication with Topamax.
In case of overdose or accidental ingestion, you can also consult the Toxicological Information Service, Phone 91 5620420.
If you forgot to take Topamax
If you interrupt treatment with Topamax
Do not stop treatment without your doctor's instructions. Your symptoms may return. If your doctor decides that you should stop taking this medication, they will gradually reduce your dose over several days.
If you have any other questions about the use of this product, ask your doctor or pharmacist.
Like all medications, this medication may have side effects, although not everyone will experience them.
Consult your doctor or seek immediate medical attention if you experience the following side effects:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)(may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)(may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)(may affect up to 1 in 1,000 people)
Unknown (cannot be estimated from available data):
Other side effects include the following, if severe, please consult your doctor or pharmacist:
Very common (may affect more than 1 in 10 people)(may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)(may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)(may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)(may affect up to 1 in 1,000 people)
Unknown (cannot be estimated from available data)
Other side effects in children
Generally, side effects observed in children are similar to those observed in adults, but the following side effects may be more frequent in children than in adults:
Other side effects that may appear in children are:
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through theSistema Español de Farmacovigilancia de Medicamentos de Uso Humano:https://www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the blister/packaging/container after CAD. The expiration date is the last day of the month indicated.
Do not store at a temperature above25°C.
Blister packs: Store in the original packaging to protect the tablets from moisture.
Bottles: Store in the original packaging and keep the bottle perfectly closed to protect the tablets from moisture.
Medicines should not be disposed of through drains or in the trash.Deposit the containers and medicines you no longer need at theSIGREpharmacy drop-off point. If in doubtask your pharmacist how to dispose of the containers and medicines you no longer need. By doing so, you will help protect the environment.
Composition of Topamax
1 OPADRY contains: hypromellose, macrogol, polisorbate 80, and as a colorant, titanium dioxide E171 and iron oxide yellow E172.
100 mg: yellow, round, 9 mm diameter tablets with the inscription "TOP" on one face and "100" on the other face.
Transparent plastic bottle with a child-resistant closure containing 20, 28, 30, 50, 56, 60, 100 or 200 (2x100) tablets. Each bottle includes a desiccant that should not be ingested.
Aluminum/aluminum blister pack. Package sizes: 10, 20, 28, 30, 50, 56, 60, 100 or 200 (2x100) tablets. Each blister pack (alu/alu) is contained within a protective pouch.
Only some package sizes may be marketed.
JANSSEN-PHARMA, S.L.
Pº de las Doce Estrellas, 5-7
28042 Madrid
Spain
Responsible manufacturer
Janssen Pharmaceutica NV
Turnhoutseweg 30,
Belgium
or
Janssen-Cilag SpA
Via C. Janssen,
Borgo San Michele
04100
Latina
Italy
or
Lusomedicamenta – Sociedade Técnica Farmacêutica S.A.
Estrada Consiglieri Pedroso nº 69 B
Queluz de Baixo
2730-055 Barcarena
Portugal
This medicine is authorized in the member states of the European Economic Area with the following names:
Austria, Belgium, Cyprus, Czech Republic, Estonia, Germany, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain: | Topamax |
Denmark, Finland, Iceland, Norway, Sweden: | Topimax |
France: | Epitomax |
Greece: | Topamac |
Last review date of this leaflet:March 2024.
Other sources of information
The most recent approved patient guide information for this medicine is available by scanning the following QR code with a smartphone. The same information is also available on the following website (URL):
https://cima.aemps.es/cima/DocsPub/16/3252
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/).
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.